Carbamylated-oxidized LDL: Proatherosclerotic effects on endothelial cells and macrophages

Journal of Atherosclerosis and Thrombosis

Volumn 20, Issue 12, 2013, Pages 878-892

  Apostolov, Eugene O ^a   Ok, Ercan ^a,b   Burns, Samuel ^a   Nawaz, Safia ^a   Savenka, Alena ^a   Shah, Sudhir V ^a,c   Basnakian, Alexei G ^a,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Atherosclerosis; Carbamylated LDL; Carbamylated oxidized LDL; Endothelial cells; Foam cells; Oxidized LDL; Scavenger receptors

Indexed keywords

BROXURIDINE; CARBAMYLATED LOW DENSITY LIPOPROTEIN; CD36 ANTIGEN; FLUORESCENT DYE; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; SCAVENGER RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS ASSAY; ARTICLE; ATHEROSCLEROSIS; CALORIMETRY; CELL COUNT; CELL DEGENERATION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MOUSE; NICK END LABELING; NONHUMAN; RECEPTOR BINDING ASSAY;

ATHEROSCLEROSIS; CARBAMATES; CELL DEATH; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IN SITU NICK-END LABELING; LIPOPROTEINS, LDL; MACROPHAGES; OXIDATION-REDUCTION;

EID: 84890855247     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.14035     Document Type: Article

References (31)

1. Nissenson AR, Pereira BJ, Collins AJ, Steinberg EP,: Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization. Am J Kidney Dis, 2001; 37: 1177-1183
2. Galle J, Hansen-Hagge T, Wanner C, Seibold S,: Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis, 2005
3. Van Tits L, De Graaf J, Hak-Lemmers H, Bredie S, Demacker P, Holvoet P, Stalenhoef A,: Increased levels of low-density lipoprotein oxidation in patients with familial hypercholesterolemia and in end-stage renal disease patients on hemodialysis. Lab Invest, 2003; 83: 13-21
4. Gonen B, Goldberg AP, Harter HR, Schonfeld G: Abnormal cell-interactive properties of low-density lipoproteins isolated from patients with chronic renal failure. Metabolism, 1985; 34: 10-14
5. Kraus LM, Kraus AP Jr: Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl, 2001; 78: S102-107
6. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, Reynolds WF, Topol EJ, DiDonato JA, Hazen SL: Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med, 2007; 13: 1176-1184
7. Horkko S, Savolainen MJ, Kervinen K, Kesaniemi YA: Carbamylation-induced alterations in low-density lipo-protein metabolism. Kidney Int, 1992; 41: 1175-1181
8. Roxborough HE, Young IS: Carbamylation of proteins and atherogenesis in renal failure. Med Hypotheses, 1995; 45: 125-128
9. Apostolov EO, Shah SV, Ok E, Basnakian AG: Quantification of carbamylated LDL in human sera by a new sandwich ELISA. Clin Chem, 2005; 51: 719-728
10. Apostolov EO, Shah SV, Ok E, Basnakian AG: Carba-mylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. Arte-rioscler Thromb Vasc Biol, 2007; 27: 826-832
11. Ok E, Basnakian AG, Apostolov EO, Barri YM, Shah SV: Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease. Kidney Int, 2005; 68: 173-178
12. Apostolov EO, Basnakian AG, Yin X, Ok E, Shah SV: Modified LDLs induce proliferation-mediated death of human vascular endothelial cells through MAPK pathway. Am J Physiol Heart Circ Physiol, 2007; 292: H1836-1846
13. Apostolov EO, Ray D, Alobuia WM, Mikhailova MV, Wang X, Basnakian AG, Shah SV: Endonuclease G mediates endothelial cell death induced by carbamylated LDL. Am J Physiol Heart Circ Physiol, 2011; 300: H1997-2004
14. Apostolov EO, Shah SV, Ray D, Basnakian AG: Scavenger receptors of endothelial cells mediate the uptake and cellular proatherogenic effects of carbamylated LDL. Arterioscler Thromb Vasc Biol, 2009; 29: 1622-1630
15. Carracedo J, Merino A, Briceno C, Soriano S, Buendia P, Calleros L, Rodriguez M, Martin-Malo A, Aljama P, Ramirez R: Carbamylated low-density lipoprotein induces oxidative stress and accelerated senescence in human endo-thelial progenitor cells. Faseb J, 2011; 25: 1314-1322
16. Apostolov EO, Ray D, Savenka AV, Shah SV, Basnakian AG: Chronic Uremia Stimulates LDL Carbamylation and Atherosclerosis. J Am Soc Nephrol, 2010; 21: 1852-1857
17. Jaisson S, Pietrement C, Gillery P: Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis. Clin Chem, 2011; 57: 1499-1505
18. Zhao W, Varghese M, Yemul S, Pan Y, Cheng A, Marano P, Hassan S, Vempati P, Chen F, Qian X, Pasinetti GM: Peroxisome proliferator activator receptor gamma coacti-vator-1alpha (PGC-1alpha) improves motor performance and survival in a mouse model of amyotrophic lateral sclerosis. Mol Neurodegener, 2011; 6: 51
19. Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B: Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone, 2006; 38: 74-84
20. Basnakian AG, Shah SV, Ok E, Altunel E, Apostolov EO: Carbamylated LDL. Adv Clin Chem, 2010; 51: 25-52
21. Lam MC, Tan KC, Lam KS: Glycoxidized low-density lipoprotein regulates the expression of scavenger receptors in THP-1 macrophages. Atherosclerosis, 2004; 177: 313-320
22. De Villiers WJ, Smart EJ: Macrophage scavenger receptors and foam cell formation. J Leukoc Biol, 1999; 66: 740-746
23. Sakata N, Uesugi N, Takebayashi S, Nagai R, Jono T, Horiuchi S, Takeya M, Itabe H, Takano T, Myint T, Tani-guchi N: Glycoxidation and lipid peroxidation of low-density lipoprotein can synergistically enhance atherogen-esis. Cardiovasc Res, 2001; 49: 466-475
24. Chiu JH, Peng YN, Yang YL, Tsai MH, Ho YL, Wu CY, Liu MY: In vitro oxidized and glycated human low-density lipoprotein particles characterized by capillary zone electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci, 2008; 875: 383-391
25. Boullier A, Bird DA, Chang MK, Dennis EA, Friedman P, Gillotre-Taylor K, Horkko S, Palinski W, Quehenberger O, Shaw P, Steinberg D, Terpstra V, Witztum JL: Scavenger receptors, oxidized LDL, and atherosclerosis. Ann N Y Acad Sci, 2001; 947: 214-222; discussion 222-213
26. Avogaro P, Bon GB, Cazzolato G: Presence of a modified low density lipoprotein in humans. Arteriosclerosis, 1988; 8: 79-87
27. Orso E, Grandl M, Schmitz G: Oxidized LDL-induced endolysosomal phospholipidosis and enzymatically modified LDL-induced foam cell formation determine specific lipid species modulation in human macrophages. Chem Phys Lipids, 2011; 164: 479-487
28. Shashkin P, Dragulev B, Ley K: Macrophage differentiation to foam cells. Curr Pharm Des, 2005; 11: 3061-3072
29. Nicholson AC, Febbraio M, Han J, Silverstein RL, Hajjar DP: CD36 in atherosclerosis. The role of a class B macro-phage scavenger receptor. Ann N Y Acad Sci, 2000; 902: 128-131; discussion 131-123
30. Hegyi L, Skepper JN, Cary NR, Mitchinson MJ: Foam cell apoptosis and the development of the lipid core of human atherosclerosis. J Pathol, 1996; 180: 423-429
31. Martinet W, Kockx MM: Apoptosis in atherosclerosis: focus on oxidized lipids and inflammation. Curr Opin Lipidol, 2001; 12: 535-541